Humanised mouse models: Targeting the murine p53 locus with human sequences

p53 in the Clinics

Volumn , Issue , 2013, Pages 95-108

  Hollstein, Monica ^a,b   Xu, Yang ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878758350     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3676-8_6     Document Type: Chapter

References (61)

1. Attardi LD, Donehower LA (2005) Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res 576:4-21
2. Baroni TE, Wang T, Qian H, Dearth LR, Truong LN, Zeng J et al (2004) A global suppressor motif for p53 cancer mutants. Proc Natl Acad Sci USA 101:4930-4935
3. Belteki G, Gertsenstein M, Ow DW, Nagy A (2003) Site-specific cassette exchange and germline transmission with mouse ES cells expressing phiC31 integrase. Nat Biotechnol 21:321-324
4. Bond GL, Levine AJ (2007) A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumour genetics to influence cancer in humans. Oncogene 26:1317-1323
5. Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9:701-713
6. Capecchi MR (2005) Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat Rev Genet 6:507-512
7. Chalberg TW, Portlock JL, Olivares EC, Thyagarajan B, Kirby PJ, Hillman RT et al (2006) Integration specificity of phage phiC31 integrase in the human genome. J Mol Biol 357: 28-48
8. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852
9. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS et al (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221
10. Donehower LA, Lozano G (2009) 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9:831-841
11. Dudgeon C, Kek C, Dmeidov ON, Saito S, Fernandes K, Diot A et al (2006) Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene. Cancer Res 66: 2928-2936
12. Feng L, Hollstein M, Xu Y (2006) Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle 5:2812-2819
13. Frank A, Leu J, Zho Y, Devarajan K, Nedelko T, Klein-Szanto A, Hollstein M, Murphy ME (2011) The codon 72 polymorphism of p53 regulates interaction with NF-kB and transactivation of genes involved in immunity and inflammation. Mol Cell Biol 31:1201-1213
14. Fraser JA, Vojtesek B, Hupp TR (2010) A novel p53 phosphorylation site within the MDM2 ubiq-uitination signal. J Biol Chem 285:37762-37772
15. Freese KK, Tuveson DA (2007) Maximizing mouse cancer models. Nat Rev Cancer 7:645-658
16. Glaser S, Anastassiadis K, Stewart AF (2005) Current issues in mouse genome engineering. Nat Genet 37:1187-1193
17. Goh AM, Coffin CR, Lane DP (2010) The role of mutant p53 in human cancer. J Pathol 223:116-126
18. Groth AC, Olivares EC, Thyagarajan B, Calos MP (2000) A phage integrase directs efficient site-specific integration in human cells. Proc Natl Acad Sci USA 97:5995-6000
19. Hahn WC, Weinberg RA (2002) Modelling the molecular circuitry of cancer. Nat Rev Cancer 2:331-341
20. Hainaut P, Hollstein M (2000) The first ten thousand mutations. Adv Cancer Res 77:81-137
21. Hergenhahn M, Luo JL, Hollstein M (2003) p53 designer genes for the modern mouse. Cell Cycle 3:738-741
22. Hollstein M, Hainaut P (2010) Massively regulated genes: the example of TP53. J Pathol 220:164-173
23. Hu W, Feng Z, Atwal GS, Levine AJ (2008) p53: a new player in reproduction. Cell Cycle 7:848-852
24. Ishizaki H, Song GY, Srivastava T, Carroll KD, Shahabi V, Manuel ER (2010) Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. J Immunother 33:609-617
25. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1-7
26. Kenzelmann Broz D, Attardi LD (2010) In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. Carcinogenesis 31:1311-1318
27. Kruse JP, Gu W (2009) Modes of p53 regulation. CeU 137:609-622
28. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-972
29. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E et al (2005) p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 7:165-171
30. Liu DP, Song H, Xu Y (2010) A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 29:949-956
31. Liu Z, Hergenhahn M, Schmeiser HH, Wogan GN, Hong A, Hollstein M (2004) Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci USA 101:2963-2968
32. Liu Z, Muehlbauer KR, Schmeiser HH, Hergenhahn M, Belharazem D, Hollstein M (2005) p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res 65:2583-2587
33. Lozano G (2010) Mouse models of p53 functions. Cold Spring Harb Perspect Biol 2:a001115
34. Luo JL, Yang Q, Tong WM, Hergenhahn M, Wang ZQ, Hollstein M (2001) Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20:320-328
35. Murray-Zmijewski F, Slee EA, Lu X (2008) A complex barcode underlies the heterogeneous response of p53 to stress. Nature Rev Mol Cell Biol 9:702-712
36. Nedelko T, Arlt VM, Phillips DH, Hollstein M (2009) TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumors. Int J Cancer 124:987-990
37. Nelson CM, Bissell MJ (2006) Of extracellular matrix, scaffolds, and signalling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 22:287-309
38. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T et al (2000) p53AIPl, a potential mediator of p53-dependent apoptosis and its regulation by Ser-46-phosphorylated p53. Cell 102:849-862
39. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847-860
40. Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2(l):a001008
41. Otsuka K, Kato S, Kakudo Y, Mashiko S, Shibata H, Ishioka C (2007) The screening of the second-site suppressor mutations of the common p53 mutants. Int J Cancer 121:559-561
42. Pfeifer GP, Besaratinia A (2009) Mutational spectra of human cancer. Hum Genet 125:493-506
43. Raymond CS, Soriano P (2007) High-efficiency FLP and PMC31 site-specific recombination in mammalian cells. PLoS One 2:el62
44. Reinbold M, Luo JL, Nedelko T, Jerchow B, Murphy ME, Whibley C et al (2008) Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene 27:2788-2794
45. Song GY, Gibson G, Haq W, Huang EC, Srivasta T, Hollstein M, Daftarian P, Wang Z, Diamond D, Ellenhorn JDI (2007a) An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol Immunother 56:1193-1205
46. Song H, Hollstein M, Xu Y (2007b) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9:573-580
47. Soussi T, Caron de Fromentel C, May P (1990) Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952
48. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, McMahon SB (2006) Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24: 841-851
49. Tang W, Ehrlich I, Wolff SB, Michalski AM, Wolf S, Hasan MT et al (2009) Faithful expression of multiple proteins via 2A-peptide self-processing: a versatile and reliable method for manipulating brain circuits. J Neurosci 29:8621-8629
50. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W (2008) Acetylation is indispensable for p53 activation. Cell 133:612-626
51. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo Veritas. Nature Rev Cancer 6:909-923
52. Toledo F, Liu CW, Lee CJ, Wahl GM (2006) RMCE-ASAP: a gene targeting method for ES and somatic cells to accelerate phenotype analyses. Nucleic Acids Res 34:e92
53. Van Dyke T, Jacks T (2002) Cancer modelling in the modern era: progress and challenges. Cell 108:135-144
54. Vom Brocke J, Schmeiser HH, Reinbold M, Hollstein M (2006) MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 27:2141-2147
55. Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137:413-431
56. Wahl GM (2006) Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo. Cell Death Differ 13:973-983
57. Wei QX, Odell AF, van der Hoeven F, Hollstein M (2011) Rapid derivation of genetically related mutants from embryonic cells harbouring a recombinase-specific Trp53 platform. Cell Cycle 10:1261-1270
58. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nature Rev Cancer 9:95-107
59. Whibley C, Odell AF, Nedelko T, Balaburski G, Murphy M, Liu Z et al (2010) Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. J Biol Chem 285:11326-11335
60. Xu Y (2008) Induction of genetic instability by gain-of-function p53 cancer mutants. Oncogene 27:3501-3507
61. Zhu F, Dolle MET, Berton TR, Kuiper RV, Capps C, Espejo A et al (2010) Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res 70:5851-5859